AstraZeneca will present over 75 abstracts, including studies on albuterol/budesonide therapy for asthma and triple inhaled therapy for COPD. Biodesix will present data on Nodify Lung tests, ...
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and nine months ended December 29, 2024. All ...
Please provide your email address to receive an email when new articles are posted on . ATS 2025 keynote series topics include caring for unhoused individuals and genetic therapy development. ATS put ...
Connect Biopharma to present data on rademikibart for asthma and COPD at ATS 2025, initiating Phase 2 trials in 2025. Connect Biopharma Holdings Limited announced its plans to present four posters at ...
ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today announced that it has reached a settlement agreement (the “Agreement”) with its Electric Vehicle (“EV”) customer with respect to the ...
Welcome to the ATS Corporation Third Quarter Conference Call and Webcast. This call is being recorded on February 5, 2025 at 8:30 a.m. Eastern time. Following the presentation, we will conduct a ...
Our ATS events series is back for 2025, landing in three global hubs: Singapore, London, and Tokyo. Here’s what to expect, and where to get your tickets... The events bring together industry leaders ...
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Ryan McLeod, Interim Chief Executive Officer, and Anne Cybulski, Interim Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results